MA43170A - Association d'un inhibiteur de bcl-2 et d'un inhibiteur de mek pour le traitement du cancer - Google Patents

Association d'un inhibiteur de bcl-2 et d'un inhibiteur de mek pour le traitement du cancer

Info

Publication number
MA43170A
MA43170A MA043170A MA43170A MA43170A MA 43170 A MA43170 A MA 43170A MA 043170 A MA043170 A MA 043170A MA 43170 A MA43170 A MA 43170A MA 43170 A MA43170 A MA 43170A
Authority
MA
Morocco
Prior art keywords
inhibitor
bcl
cancer
treatment
combination
Prior art date
Application number
MA043170A
Other languages
English (en)
Inventor
Lina Han
Marina Yurievna Konopleva
Mark Merchant
Deepak Sampath
Original Assignee
Univ Texas
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas, Genentech Inc filed Critical Univ Texas
Publication of MA43170A publication Critical patent/MA43170A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA043170A 2015-11-03 2016-11-03 Association d'un inhibiteur de bcl-2 et d'un inhibiteur de mek pour le traitement du cancer MA43170A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562250231P 2015-11-03 2015-11-03
US201562263082P 2015-12-04 2015-12-04

Publications (1)

Publication Number Publication Date
MA43170A true MA43170A (fr) 2018-09-12

Family

ID=57471995

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043170A MA43170A (fr) 2015-11-03 2016-11-03 Association d'un inhibiteur de bcl-2 et d'un inhibiteur de mek pour le traitement du cancer

Country Status (13)

Country Link
US (2) US10959993B2 (fr)
EP (1) EP3370775B1 (fr)
JP (1) JP6724136B2 (fr)
KR (1) KR102124715B1 (fr)
CN (1) CN108601839B (fr)
AU (1) AU2016349279A1 (fr)
BR (1) BR112018008882A8 (fr)
CA (1) CA3001880C (fr)
HK (1) HK1259545A1 (fr)
IL (1) IL258741B (fr)
MA (1) MA43170A (fr)
MX (1) MX2018005233A (fr)
WO (1) WO2017079399A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9539251B2 (en) * 2012-09-07 2017-01-10 Genentech, Inc. Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor
GB201809746D0 (en) * 2018-06-14 2018-08-01 Berlin Chemie Ag Pharmaceutical combinations
TW202023568A (zh) * 2018-07-30 2020-07-01 瑞典商阿斯特捷利康公司 用於治療癌症之組合療法
CA3116321A1 (fr) * 2018-10-16 2020-04-23 The Johns Hopkins University Compositions et methodes permettant de traiter la maladie d'ehlers-danlos et les troubles associes
WO2020181219A1 (fr) * 2019-03-06 2020-09-10 The Regents Of The University Of Colorado, A Body Corporate Méthodes de dépistage et de traitement de la leucémie myéloïde résistante au venetoclax
WO2020223351A1 (fr) * 2019-04-29 2020-11-05 Immunogen, Inc. Combinaisons thérapeutiques comprenant des immunoconjugués anti-cd123
EP3976200A4 (fr) * 2019-06-03 2023-07-05 Sanford Burnham Prebys Medical Discovery Institute Utilisations de partenaires létaux synthétiques pour le traitement du cancer
US11957701B2 (en) 2020-07-17 2024-04-16 Delta-Fly Pharma, Inc. Therapy and new therapeutic agent for blood cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2927656C (fr) 2005-10-07 2019-09-24 Exelixis, Inc. Azetidines en tant qu'inhibiteurs de mek
MX2010012064A (es) * 2008-05-05 2010-12-06 Schering Corp Uso secuencial de agentes quimioterapeuticos citotoxicos para el tratamiento de cancer.
US20100009934A1 (en) * 2008-06-09 2010-01-14 Combinatorx, Incorporated Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
US20120277210A1 (en) 2010-10-29 2012-11-01 Abbott Laboratories Solid dispersions containing an apoptosis-inducing agent
ES2603129T3 (es) 2010-11-23 2017-02-23 Abbvie Ireland Unlimited Company Métodos de tratamiento utilizando inhibidores selectivos de Bcl-2
NZ610151A (en) 2010-11-23 2015-06-26 Abbvie Inc Salts and crystalline forms of an apoptosis-inducing agent
BR112014004587A2 (pt) * 2011-08-31 2017-03-14 Novartis Ag combinações sinérgicas de inibidores de pi3k- e de mek
NZ744862A (en) 2012-08-17 2019-06-28 Hoffmann La Roche Combination therapies for melanoma comprising administering cobimetinib and vemurafenib
US9539251B2 (en) 2012-09-07 2017-01-10 Genentech, Inc. Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor
US10111897B2 (en) * 2013-10-03 2018-10-30 Duke University Compositions and methods for treating cancer with JAK2 activity

Also Published As

Publication number Publication date
US20180303815A1 (en) 2018-10-25
US10959993B2 (en) 2021-03-30
AU2016349279A1 (en) 2018-05-10
JP2018534298A (ja) 2018-11-22
BR112018008882A8 (pt) 2019-02-26
US20210169865A1 (en) 2021-06-10
HK1259545A1 (zh) 2019-11-29
CA3001880A1 (fr) 2017-05-11
JP6724136B2 (ja) 2020-07-15
KR20180054852A (ko) 2018-05-24
MX2018005233A (es) 2019-04-29
KR102124715B1 (ko) 2020-06-18
CN108601839A (zh) 2018-09-28
WO2017079399A1 (fr) 2017-05-11
CA3001880C (fr) 2021-08-17
CN108601839B (zh) 2021-10-26
EP3370775B1 (fr) 2023-04-19
IL258741A (en) 2018-06-28
BR112018008882A2 (pt) 2018-11-06
EP3370775A1 (fr) 2018-09-12
IL258741B (en) 2021-08-31

Similar Documents

Publication Publication Date Title
MA49144A (fr) Polythérapies pour le traitement du cancer
MA43170A (fr) Association d'un inhibiteur de bcl-2 et d'un inhibiteur de mek pour le traitement du cancer
MA50082A (fr) Inhibiteurs d'enpp1 et leur utilisation pour le traitement du cancer
MA45192A (fr) Traitement d'association
MA43135A (fr) Compositions et méthodes pour le du traitement du cancer
MA45037A (fr) Polythérapie à base d'arnm pour le traitement du cancer
MA42420A (fr) Vaccins pour le traitement et la prévention du cancer
MA43283A (fr) Procédés et compositions pour le traitement du cancer
MA44699A (fr) Association d'un antagoniste du pd-1 et d'un oligonucléotide cpg du type c pour le traitement du cancer
MA55697A (fr) Molécules d'anticorps pour le traitement du cancer
MA45539A (fr) Dihydropyranopyrimidines pour le traitement d'infections virales
MA42819A (fr) Procédés pour le traitement d'infections virales à arenaviridae et coronaviridae
MA47310A (fr) Combinaisons de cabozantinib et d'atzolizumab pour traiter le cancer
MA42439A (fr) Agents, utilisations et procédés pour le traitement d'une synucléinopathie
MA48637A (fr) Polythérapies pour le traitement du cancer
MA50409A (fr) Polythérapies pour le traitement du cancer
MA46836A (fr) Agents, utilisations et procédés pour le traitement d'une synucléinopathie
MA45429A (fr) Polythérapie pour le traitement du cancer
MA43000A (fr) Polythérapie pour le traitement de tumeurs malignes
MA50849A (fr) Substances et procédés pour le traitement d'hémoglobinopathies
MA41555A (fr) Polythérapie pour le traitement du cancer
MA42999A (fr) Polythérapie pour le traitement de malignités
MA41123A (fr) Polythérapie pour le traitement du cancer
MA44700A (fr) Combinaison d'un anticorps anti-il-10 et d'un oligonucléotide de type cpg-c pour le traitement du cancer
MA45973A (fr) Combinaisons d'inhibiteurs de btk pour le traitement du myélome multiple